Christian Wyss
lic. iur., LL.M.
Attorney at Law
Partner

Languages: German, English, French
Contact: +41 58 211 33 39, cwyss@vischer.com

General
Christian Wyss specializes in drafting and negotiating contracts for clients from the Life Sciences and Information Technology industries. Christian has extensive experience with technology transfer and license agreements, research, development or marketing co-operations, clinical trial agreements, contract manufacturing agreements and distribution agreements. He regularly works with clients in financing rounds, acquisitions, or joint ventures and assists with intellectual property related issues in M&A transactions. Christian also advises on implementing compliance with the Swiss data protection laws.

Education
- Wake Forest University School of Law (LL.M., 2005)
- University of Basel (lic. iur., 2000)
- University of Lausanne (1998/1999)
Teams
Corporate and Commercial, Startup Desk, Data & Privacy, Information and Communication Technology, Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Private Equity, Venture Capital, Corporate Finance, Restructuring and Insolvency

Practice Areas

References

Legal 500 (EMEA 2018) - "Healthcare and life sciences" - Tier 1
"Vischer provides transactional, financing, capital markets, product launch and regulatory advice to health and life sciences industry clients and further represents them in contentious matters. The practice assisted JSR Corporation with its acquisition of Selexis and advised Axovant Sciences on its debt financing agreement with Hercules Capital. Stefan Kohler jointly heads the practice with Matthias Staehelin; Christian Wyss is another name to note."

Chambers Europe (2018) - "Life Sciences"
"Christian Wyss enters the rankings for the first time on the back of strong client support. One client enthuses that he is 'responsive, knowledgeable, considerate and intelligent.' Another source notes that he is 'careful in listening to the needs of the customer' and is a 'clear communicator.' His work includes assisting T3 Pharmaceuticals with various financing and licence agreements. He has further capabilities advising on acquisitions and collaborative agreements within the life sciences sector."

Legal 500 (EMEA 2017) - "TMT"
"Vischer’s ‘highly skilled’ team assisted insurer Sympany with negotiating IT contracts and has been advising Ring Central on data protection and telecoms regulatory matters. Other clients include 3 Plus, Netflix and Swisscom. Rolf Auf der Maur and Christian Wyss are recommended."

Legal 500 (EMEA 2016) - "Healthcare and Life Sciences" - 1st tier
"Vischer has an ‘excellent’ regulatory practice, including compliance and administrative procedures, remarkable IP capabilities and a niche in acting for emerging biotech companies, where it advised GlycoVaxyn and Redvax on their sales to GlaxoSmithKline and Pfizer, respectively. Other clients include AstraZeneca, Novartis, Mattern Pharmaceuticals and IVF Zentren Prof. Zech. Stefan Kohler has ‘very broad knowledge’, including regulatory and IP matters, and is recommended along with Matthias Staehelin and newly promoted partner Christian Wyss."

Deals

Azafaros B.V. gets seed funding
Azafaros (www.azafaros.com), a biotech company established in Leiden in the Netherlands, focusing on the development of new therapies in the field of rare metabolic disorders, announced the closing of a seed financing round. BioGeneration Ventures is the founding investor.
Olivier Morand, Ph.D. and IMD alumnus, is joining Azafaros as Chief Executive Officer and member of the Board of Directors.

VISCHER advised on all Swiss legal issues related to the transaction. The VISCHER team includes Christian Wyss (Partner, Corporate/M&A), Marc Prinz (Partner, Employment) and Vera Keller (Junior Associate, Corporate/M&A).

**AC Immune issues up to 10 Million Common Shares**

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, issues up to 10 million new common shares at a price of USD 11.75 per share. This offering price will be the same for a total of three offerings, namely (1) a first subscription rights offering for shareholders, (2) a primary offering for institutional investors and (3) a second subscription rights offering for shareholders. An aggregate of 7'391'305 shares were sold in the first subscription rights offering and primary offering. In addition, the underwriters exercised the overallotment option (“greenshoe”) to purchase an additional 1'108'695 shares. The Company expects gross proceeds from the offerings including the underwriters’ option to purchase additional shares, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately USD 99.9 million.

Jefferies LLC, Leerink Partners LLC and UBS Investment Bank were acting as joint book-running managers for the first subscription rights offering and the primary offering. The second subscription rights offering will consist of up to 1.5 million newly issued common shares.

VISCHER AG and Davis Polk & Wardwell LLP are legal advisors to the Company. VISCHER AG has been advising AC Immune since inception in 2003. The team at VISCHER is led by Matthias Staehelin (Partner Corporate) with Stefan Grieder (Partner Corporate), Nadia Tarolli (Partner Tax), Christian Wyss (Partner Corporate), Vincent Reardon, Angelo Imperiale and Eric Flückiger (all Associates).

**Immunotherapy startup Anaveon supported by UZH Life Sciences Fund**

With the help of investments of the UZH Life Sciences Fund and the BaseLaunch funding programme, Onur Boyman and Andreas Katopodis founded the spin-off Anaveon AG. Onur Boyman, Director of the Department of Immunology at the University Hospital of Zurich and Professor at the Faculty of Medicine of the University of Zurich, and Andreas Katopodis, previously Director at the Novartis Institutes of Biomedical Research, have developed an antibody based on years of research by Onur Boyman. Anaveon plans to develop this antibody into a cancer drug. Melanoma and renal and lung carcinomas are the main indications. Anaveon’s antibody re-directs Interleukin-2, an immune growth factor, to preferential promote proliferation of a class of T-cells against cancer cells. At the same time, the Anaveon-antibody reduces undesirable side effects of Interleukin-2 cancer therapy resulting in a better therapeutic window.

VISCHER advises Anaveon AG on legal and tax issues. The VISCHER team is led by Christian Wyss (Corporate) and Nadia Tarolli (Tax) and includes Moritz Jäggy (Corporate), Nora Heuberger (Tax), Fiona Gao (Corporate) and Sara Ianni (Employment).

**Paprec issued EUR 800 Million Green Bond**

Paprec group offers recycling solutions for all types of waste with more than 200 sites in France and Switzerland. Paprec Group issued a green bond (“dette obligataire verte”), confirmed by an independent second party opinion to be aligned with the Green Bond Principles, in the amount of EUR 800 million, i.e. EUR 575 million in aggregate principal amount of 4% Senior Secured Notes due 2025 and EUR 225 million in aggregate principal amount of Senior Secured Floating Rate Notes due 2025. In addition to the bond offering, a EUR 200 million super senior revolving credit facility was signed with a syndicate of banks.

VISCHER acted as Swiss counsel to Paprec in connection with the EUR 1 billion financing. The team was led by Dr. Adrian Dörig (Partner, Banking & Finance) with the support of Seraina Tsering (Senior Associate, Banking &
Lundbeck to acquire Prexton Therapeutics
H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) announced signing of a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay EUR 100m upfront and is furthermore required to later pay up to EUR 805m in development and sales milestones to the group of current owners. By acquiring Prexton, Lundbeck will obtain global rights of foliglurax, which currently is in clinical phase II testing for symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia (uncontrolled movements) including Levodopa Induced Dyskinesia (LID). The aim is to treat the motor symptoms of Parkinson’s disease, such as resting tremor and dyskinesia.

VISCHER advised Lundbeck as lead-counsel in this transaction. The team was led by Corporate partners Christian Wyss and Robert Bernet and included Luzius Zumstein, Gian Caprez, Gian Geel, Aron Waltuch (all Corporate), Marc Prinz (Employment) and Eric Flückiger (Tax).

Polyphor licenses worldwide exclusive rights for POL6014 to Santhera
Polyphor AG, a clinical stage, privately held Swiss specialty pharma company, has entered into an exclusive, global license agreement with Santhera Pharmaceuticals to further develop and commercialize the inhaled neutrophil elastase inhibitor, POL6014, in Cystic Fibrosis (CF) and other neutrophilic lung diseases. Under the terms of the agreement, Polyphor will receive an upfront payment of CHF 6.5 m paid in the form of Santhera shares and could receive up to an additional CHF 121 m in potential development, regulatory and sales milestones for the initial indication, as well as tiered double-digit royalties on sales. Santhera will have the exclusive worldwide rights to develop and commercialize POL6014, and assume full responsibility for its development within agreed timelines.

VISCHER advised Polyphor AG in the negotiations. The VISCHER team includes Christian Wyss (partner, corporate), Dr. Matthias Staehelin (partner, corporate) and Sebastian Flückiger (associate, corporate).

ImmunOs Therapeutics AG closes CHF 2.3m Financing Round
ImmunOs Therapeutics AG, a Swiss bio-technology company leading development of a next generation innate and adaptive immunity focused immuno-therapy platform for cancer, announced the closing of its 2.3 Million CHF financing round. The proceeds of the financing will be used to advance its lead clinical candidate, a single multitasking protein agent, for treating solid tumors.

VISCHER acted as counsel to ImmunOs. The team was led by Christian Wyss (Partner) and supported by Luzius Zumstein (Associate), both Corporate.

Balderton Capital invests in Sophia Genetics USD 30m series D round
Balderton Capital, a London-based venture capital fund with a focus on ambitious entrepreneurs, disruptive technology and sustainable businesses, led the series D financing round over USD 30m in Sophia Genetics SA, one of the world’s foremost companies in the field of applying artificial intelligence to genomic analysis.

VISCHER acted as transaction counsel to Balderton Capital. The team was led by Christian Wyss (Partner) and supported by Luzius Zumstein (Associate) and Aron Waltuch (Trainee), all Corporate.

JSR Corporation Acquires Pioneering Cell Line Developer Selexis SA
JSR Corporation, listed on Tokyo Stock Exchange, recently completed its acquisition of Selexis SA, a pioneering life sciences company and global leader in mammalian cell-line generation technologies.

JSR was represented by Transatlantic Law International (TALI) and VISCHER as the Swiss M&A legal counsel. The VISCHER team was led by Christian Wyss, partner and head of the VISCHER Corporate & Commercial practice team,
and included Gian-Andrea Caprez (managing associate, M&A), Marc Prinz (partner, employment) and Nadia Tarolli (partner, tax).

JSR Corporation, through its business unit JSR Life Sciences, provides specialized materials and products to the biotech industry. JSR Life Sciences operates a network of manufacturing facilities, sales offices and R&D labs in key markets throughout North America, Europe and Asia-Pacific.

Read the press release here: www.transatlanticlaw.com/content/jsr-corporation-acquires-pioneering-cell-line-developer-selexis-sa

Inthera Bioscience raises CHF 10.5 million in series A financing round
VISCHER advises Inthera Bioscience AG, a Zurich based biopharmaceutical company, developing first-in-class targeted small molecule therapies for solid tumors. The CHF 10.5 m (EUR 9.6 m) series A financing round was led by Merck Ventures, with equal contribution from Aglaia BioMedical Ventures and Novo Seeds and the participation of a private investor. In conjunction with the financing round, Emmanuelle Coutanceau of Novo Seeds and Keno Gutierrez of Merck Ventures have joined the company’s Board of Directors. Earlier this year, the Board of Directors had already been strengthened with two experienced biotech executives, Klaus Schollmeier, who has assumed the Chairman role, and Anker Lundemose, joining as independent member.

The VISCHER team includes Christian Wyss (Partner), Dania Salvisberg-Schneider (Senior Associate), both Corporate and Nadia Tarolli (Partner), Tax.

T3 Pharmaceuticals closes financing round
VISCHER assisted T3 Pharmaceuticals AG, a Basel based biotechnology spin-off from the Biozentrum of the University of Basel, in converting from GmbH to AG and closing the Series A Financing Round. T3 Pharmaceuticals develops bacteria-based cancer therapies. The live bacteria infect solid tumors and fight them with a proprietary protein delivery technology developed at the University of Basel. With the latest financing round, T3 Pharmaceuticals can now advance initial lead candidates into preclinical development. The VISCHER team includes Christian Wyss and Dr. Matthias Staehelin (both Partner) and Dania Salvisberg-Schneider (Senior Associate) all Corporate.

Biovotion extends Series A Financing Round
VISCHER assists Harmony Medical Inc. as investor in the second closing of the ongoing CHF 10 m Series A financing round of Biovotion Ltd., Zürich. Biovotion Ltd is a leading wearable physiology monitoring company and provides integrated solutions with connected hardware and value-added monitoring services. Biovotion Ltd’s digital health solutions support users in keeping a healthy lifestyle, improve healthcare treatment outcomes, and aiming to reduce cost of health provision. Harmony Medical Inc. specializes in global healthcare investments and supports its portfolio companies in accessing the healthcare markets in China, Hong Kong and several other markets in the region. The team at VISCHER includes Christian Wyss and David Jenny.

AC Immune prices Upsized Initial Public Offering
AC Immune SA announced the pricing of its upsized initial public offering of 6,000,000 of its common shares at the initial public offering price of $11.00 per common share at NASDAQ. AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. AC Immune’s common shares have been approved for listing on the NASDAQ and are expected to begin trading under the ticker symbol "ACIU" on
Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. VISCHER AG and Davis Polk & Wardwell London LLP are legal advisors to the Company. VISCHER AG has been advising AC Immune since inception in 2003. The team at VISCHER is led by Matthias Staehelin (Partner Corporate) with Stefan Grieder (Partner Corporate), Nadia Tarolli (Partner Tax), Christian Wyss (Partner Corporate), Vincent Reardon, Angelo Imperiale and Eric Flückiger (all Associates).

**ABBA Therapeutics enters into OmniAB® Platform License Agreement**
ABBA Therapeutics AG, a Swiss biotechnology company developing innovative immuno-oncology therapies, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) have entered into a worldwide license agreement. Under the license, ABBA Therapeutics AG will be able to use the OmniRat, OmniMouse and OmniFlic platforms to generate fully human mono- and bispecific antibodies.

VISCHER advised ABBA Therapeutics AG in the negotiations. The VISCHER team includes partner Christian Wyss and Luzius Zumstein.

**Inthera Bioscience AG Raises EUR 3.4 m in Seed Financing Round**
VISCHER advises Inthera Bioscience, a Zurich based biopharmaceutical company focused on the development of first-in-class targeted small molecule therapies for solid tumors.

The EUR 3.4 m seed financing round was led by MS Ventures, with equal contribution from Agalaia Oncology Fund II and Novo Seeds. EVA Basel also participated in the financing. Inthera has discovered potent disruptors of hypoxia-inducible signaling for the treatment of solid tumors and targeted agents against HPV-associated cancer, which are in pre-clinical development.

The VISCHER team includes Christian Wyss, Matthias Staehelin and Dania Salvisberg-Schneider (all Corporate)

**Financing Round of ADC Therapeutics with USD 80 m**
VISCHER assists AstraZeneca as investor in a USD 80 m financing round of ADC Therapeutics Sàrl, Epalinges, an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major solid and hematological cancers. ADC Therapeutics intends to use this financing to progress ADC Therapeutics’ product portfolio, including ADCT-301 for lymphoma and leukemia now in Phase I and a collaboration to develop up to two ADCs for commercialisation with MedImmune, the global biologics research and development arm of AstraZeneca.

Covington & Burling LLP and VISCHER AG advise AstraZeneca in this financing. The team at VISCHER includes Christian Wyss and Stefan Grieder.

**Research Agreement LimmaTech Biologics with GSK**
Following the acquisition GlycoVaxyn by GSK in February 2015, GSK commissioned the management team to create a new company, LimmaTech Biologics AG in Schlieren near Zurich, which acquired GlycoVaxyn’s operational research business. LimmaTech Biologics is not a GSK-owned company. GSK and LimmaTech Biologics have signed a research agreement with a minimum term of five years to allow LimmaTech Biologics to develop novel bioconjugate antigen-based vaccines exclusively for GSK. VISCHER assisted LimmaTech Biologics starting at foundation and in the collaboration agreement with GSK. The team at VISCHER is led by Matthias Staehelin (Partner) with Christian Wyss (Partner), Dania Salvisberg-Schneider (Associate), Moritz Jäggy (Associate), all Corporate and Nadia Tarolli (Partner, Tax).

**Paprec issues EUR 480 m Green Bond**
Paprec Group, the leading independent recycling company, issued a four
times oversubscribed EUR 480 m Green Bond. Paprec Group is the first sub-
investment grade French company to issue a Green Bond.

In addition to the bond offering, a EUR 100 m super senior revolving credit
facility was signed with a syndicate of banks.

VISCHER acted as Swiss Counsel to Paprec Group in the transaction. The
team included Janusz Marty, Adrian Dörig (both Banking & Finance), Christian
Wyss (Corporate) and Christoph Niederer (Tax).

**GlycoVaxyn sold to GSK shortly before IPO**

VISCHER represents the sellers of GlycoVaxyn AG, in its sale to
GlaxoSmithKline (GSK) for a consideration of $190 million, valuing this
privately held Swiss vaccine company in Schlieren-Zurich at $212 million in
total. GlycoVaxyn’s innovative biological conjugation platform originates from
ETH Zurich and enables the development of a new generation of conjugate
vaccines against major bacterial infections. VISCHER has been assisting
several financing rounds raising approximately CHF 50 million of equity
funding with top-tier private investors including Sofinnova Partners, Index
Ventures and Edmond de Rothschild Investment Partners. VISCHER has also
been assisting the Company’s plan to go public on the Swiss Stock Exchange
in spring 2015; this IPO was close to completion prior to the sale to GSK. The
VISCHER-team is led by Dr. Matthias Staehelin (partner), Dr. Stefan Grieder
(partner, both Corporate) and Nadia Tarolli Schmidt (partner, Tax) with
Christian Wyss (partner), Moritz Jäggy (Associate), Dania Salvisberg-
Schneider (Associate) and Ruben Masar (Associate, all Corporate).

**J&J concludes with AC Immune a $509M-plus deal to partner on a tau
vaccine for Alzheimer’s**

AC Immune SA enters into a worldwide exclusive license agreement and
research collaboration with Janssen Pharmaceuticals (Johnson & Johnson,
NYSE: JNJ) to develop and commercialize therapeutic anti-Tau vaccines for the
treatment of Alzheimer’s disease and potentially other tauopathies, including
the lead therapeutic vaccine, ACI-35, that is currently in a phase Ib clinical
trial in Alzheimer’s patients. Under the terms of the agreement, AC Immune
will receive an upfront payment and is eligible to receive research,
development and commercialization milestone payments potentially totaling
up to USD 509 million (CHF 500 million as per Dec. 2014) and royalties on
net sales. Fenwick & West LLP and VISCHER AG represent AC Immune based
in Lausanne, Switzerland. The Fenwick team is led by partner Jake Handy
with Lisa Kenkel. The VISCHER team is led by partner Matthias Staehelin with
Christian Wyss.

**AC Immune SA in Lausanne raises CHF 20 million ($22.5 million)**

VISCHER advises AC Immune SA in Lausanne in its financing of CHF 20
million ($22.5 million) with existing private investors. The new funds will
mainly support the newly initiated groundbreaking clinical trial of the anti-
Ptau vaccine ACI-35 with patients with mild or moderate Alzheimer’s disease.
The VISCHER team is lead by Dr. Matthias Staehelin (Partner) with Christian
Wyss (Managing Associate) and Marius Meier (Senior Associate), all
Corporate/M&A.

**GlycoVaxyn AG enters Strategic Collaboration with GSK to Develop
New Bacterial Vaccines**

VISCHER advises GlycoVaxyn, a leader in the development of innovative
vaccines, entering into a collaboration with GlaxoSmithKline Biologicals (GSK)
to develop new bacterial vaccines. GlycoVaxyn is developing a portfolio of
novel bio-conjugate vaccines with its unique, proprietary in vivo
glycosylation platform. GlycoVaxyn located in Schlieren near Zurich is funded
by a top-tier group of private investors including Sofinnova Partners, Index
Ventures and Edmond de Rothschild Investment Partners. The VISCHER team
is led by Matthias Staehelin (Corporate) with Christian Wyss.

**GlycoVaxyn enters into Research and Development Collaboration
with Janssen Pharmaceuticals to Develop Multi-Valent Bacterial
Vaccine**

VISCHER advises GlycoVaxyn AG, a leader in the development of innovative
vaccines, entering into research and development collaboration and license
agreement with Janssen Phar-maceuticals (JPI), to develop a multi-valent
bacterial vaccine on the basis of its unique, proprietary in vivo glycosylation platform. GlycoVaxyn will collaborate with JPI’s affiliate, Crucell Holland BV, on the development of the multi-valent vaccine until proof-of-concept, after which JPI will be responsible for later-stage clinical studies and world-wide commercialization. GlycoVaxyn located in Schlieren near Zurich is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners. The VISCHER team is led by Matthias Staehelin (Corporate) with Christian Wyss.

**Accel Parnters acquires a stake in HouseTrip SA.**
VISCHER advises Accel Partners, the US based private equity and venture capital firm in their acquisition of an undisclosed stake in HouseTrip SA, the Switzerland based company that operates as an online platform for the rental of vacation properties, for a consideration of USD 40m. The VISCHER team is led by Dr. David Jenny (Partner) and Christian Wyss (Associate).

**Goldman Sachs and Doughty Hanson bid for Orange Communications AG**
Goldman Sachs and Doughty Hanson bid in the 2011 CHF 2bn auction for the Swiss mobile phone operator Orange Communications SA sold by France Telecom, but are finally outbid.

VISCHER advises Goldman Sachs and Doughty Hanson in this bid as legal advisor. The team includes Jürg Luginbühl and Felix W. Egli (co-leaders), Benedict Christ, Peter Kühn, Thomas Krizaj, Christian Wyss and Fabienne Ochsner (all M&A), Adrian Dörig and Andreas Testor (both Financing), Rolf Auf der Maur and Thomas Steiner (both regulatory), Barbara Meyer (labor law), Christoph Niederer (tax), Klaus Neff (antitrust) and Delia Bosshard (IP).

**Biogen Idec acquires Dompé shares.**
VISCHER advises Biogen Idec in the acquisition of all Dompé shares. The VISCHER team consists of Dr. David Jenny (Partner) and Christian Wyss (Associate).

**German private equity firm HANNOVER Finanz GmbH acquires the hardware business from California based and LSE listed Kofax plc.**
German private equity firm HANNOVER Finanz GmbH acquires the hardware business, comprising certain legal entities, the personnel and assets and liabilities in 19 locations throughout EMEA, from California based and LSE listed Kofax plc for a gross consideration of USD 23.3m.

VISCHER advises HANNOVER Finanz GmbH in this transaction. The team is led by partner Robert Bernet and further comprises Jana Essebier, Matthias Glatthaar (Corporate/M&A), Christian Wyss (IP/IT) and Gili Fridland Svensson (Employment).

**Saba Software acquires Comartis Group**
VISCHER advises NASDAQ listed Saba Software Inc., the premier people cloud provider, in its acquisition of Swiss-based Comartis Group, a leading company in the web-based testing and assessment market. The VISCHER team includes partner Robert Bernet (Corporate/M&A; lead), Christian Wyss (IP/IT) and Gili Fridland (Employment).

**Singapore listed Olam International Ltd purchases tropical hardwood production business of Dalhoff Larsen & Hornemann A/S.**
VISCHER acts as lead counsel for the Singapore listed Olam International Ltd in connection with the purchase of the tropical hardwood production business of Dalhoff Larsen & Hornemann A/S. The transaction includes the purchase of all the shares in the Swiss company tt Timber International AG as well as in subsidiaries in three African countries. The team includes partners Stéphane Konkoly and Michael Pfeifer and associates Christian Wyss and Janusz Marty.
Practice

- Law clerk at the Basel-Land Criminal Court
- Legal internships with a corporate law firm in Basel and at the Basel-Land Criminal Court

Memberships in Associations

- Swiss Bar Association
- Basel Bar Association
- Pro Iure
- International Bar Association
About VISCHER

We effectively support our clients in a solution oriented manner in legal, tax and regulatory matters. Our lawyers, tax experts and notaries are organized in the specialist practice teams listed below, each led by an experienced partner. This enables us to individually tailor our services to meet the requirements of the individual project in the most effective manner. Our offices are located in Zurich and Basel, the two largest business centers of Switzerland.

Independence is a key factor for the optimal protection of client interests. We therefore put great value on a very high conflict of interest standard that is no longer obvious in the international legal industry. In order to also remain independent in transborder transactions, we have built up our own global network of foreign law firms enabling us to select our foreign attorneys based exclusively on the requirements of the individual mandates and without having to take into consideration the instructions of a law firm group or a network organization.

- Antitrust and Competition
- Aviation
- Banking and Finance
- China Desk
- Civil Law Notaries
- Compliance Support
- Corporate and Commercial
- Data & Privacy
- Employment Law
- Energy
- Health Care
- Immigration
- Information and Communication Technology
- Intellectual Property
- Life Sciences, Pharma, Biotech
- Listed Companies
- Litigation, Arbitration
- Media and Entertainment
- Mergers & Acquisitions
- Pension Funds
- Private Clients
- Private Equity, Venture Capital, Corporate Finance
- Public Sector and Regulatory
- Real Estate
- Restructuring and Insolvency
- Sports Law
- Startup Desk
- Tax
- White Collar Crime

Zürich
VISCHER AG
Schützengasse 1
8021 Zürich
Switzerland
Tel +41 58 211 34 00

Basel
VISCHER AG
Aeschenvorstadt 4
4010 Basel
Switzerland
Tel +41 58 211 33 00